|
CHMP: Benefits Outweigh Cancer Risk for Pioglitazone Drugs
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) is recommending new warnings for pioglitazone Type 2 diabetes drugs, but says the benefits outweigh a small risk of developing bladder cancer.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives